Chengdu RML Technology Co., Ltd. (SHE:301050)

Revance Therapeutics Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 8, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Market Capitalization	13,007	12,447	10,194	13,446	23,601	-
Market Cap Growth	43.00%	22.10%	-24.19%	-43.03%	-	-
Enterprise Value	10,994	10,777	8,539	11,778	22,218	-
Last Close Price	53.90	51.37	40.80	53.92	94.53	-
PE Ratio	42.39	36.32	33.40	48.50	117.12	-
Forward PE	26.49	26.49	26.70	27.76	69.41	-
PS Ratio	12.34	10.55	11.51	15.63	32.11	-
PB Ratio	4.25	4.19	3.82	5.75	11.42	-
P/TBV Ratio	4.26	4.20	3.84	5.77	11.48	-
P/FCF Ratio	-	-	13.49	-	599.96	-
P/OCF Ratio	997.11	-	12.78	603.00	258.18	-
EV/Sales Ratio	10.43	9.14	9.64	13.69	30.23	-
EV/EBITDA Ratio	35.86	32.03	28.28	44.50	95.74	-
EV/EBIT Ratio	38.66	34.24	30.29	47.09	99.81	-
EV/FCF Ratio	-1450.37	-	11.30	-	564.81	-
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.03	0.15
Debt / EBITDA Ratio	0.10	0.09	0.10	0.12	0.22	0.55
Debt / FCF Ratio	-	-	0.04	-	1.30	-
Asset Turnover	0.26	0.29	0.21	0.26	0.39	0.45
Inventory Turnover	0.41	0.44	0.28	0.50	0.96	0.66
Quick Ratio	2.65	3.03	1.24	1.40	2.64	1.08
Current Ratio	4.09	5.14	2.29	2.39	3.44	1.94
Return on Equity (ROE)	10.94%	12.16%	12.20%	12.58%	15.66%	27.14%
Return on Assets (ROA)	4.35%	4.78%	4.17%	4.63%	7.36%	10.83%
Return on Capital (ROIC)	6.15%	6.90%	6.96%	6.97%	10.30%	16.48%
Return on Capital Employed (ROCE)	9.20%	10.50%	10.50%	10.60%	10.60%	25.70%
Earnings Yield	2.41%	2.75%	2.99%	2.06%	0.85%	-
FCF Yield	-0.06%	-2.70%	7.41%	-0.45%	0.17%	-
Dividend Yield	0.76%	0.82%	0.71%	0.20%	0.08%	-
Payout Ratio	39.13%	35.73%	8.92%	7.18%	1.59%	-
Buyback Yield / Dilution	-1.34%	-0.23%	-0.04%	-20.28%	-11.02%	-3.11%
Total Shareholder Return	-0.58%	0.58%	0.68%	-20.08%	-10.93%	-3.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.